CD7 CAR-T for relapsed or refractory acute leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new immune therapy called CD7 CAR-T cells for people with acute leukemia that has come back or hasn't gotten better with standard treatments. It aims to see if this treatment is safe and can help control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute leukemia that has come back or hasn't been controlled by standard chemo.
- You are between 14 and 65 years old.
- You are generally able to care for yourself (ECOG score 0-3).
- Your kidneys, liver, lungs, and heart are working well enough (checked by simple tests).
- You don't have active infections, HIV, or uncontrolled hepatitis B or C.
- You are not pregnant or breastfeeding, and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial tests a new cell therapy called CD7 CAR-T for children with high-risk T-cell lymphoblastic leukemia or lymphoma who have finished initial chemotherapy and are in remission. It aims to prevent relapse.
This trial tests a new immune cell therapy (CD7 CAR-T) given as a bridge to a stem cell transplant in people with relapsed or hard-to-treat CD7-positive leukemia. The goal is to help control the leukemia and improve chances for a successful transplant.
This trial tests a new cell therapy called CD7 CAR-T that targets a specific protein on your cancer cells. It is for people with T-cell lymphoma or T-cell leukemia that has not responded to other treatments or has come back.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.